Investor Relations
Reporting Q1 2021
Evonik has published its quarterly report Q1 2021 on May 6, 2021. You can access further information here. ... MORE
Events
Division Spotlight Series & Capital Markets Day 2021
We will be hosting a virtual "Division Spotlight Series" for our three growth divisions as well as a Capital Markets Day with our board of management. ... MORE
Further Information
Company
Events & Presentations
Here you will find dates, information and presentations on our events. ... MORE
Company
Analysts' estimates
Evonik Industries AG is covered by German and international financial analysts, who provide their own research analyses and earnings estimates in respect of the company. ... MORE
Company
News & Reports
Here you can find "Investor Relations News" with the latest news from our company, plus our most recent interim reports, annual reports and corporate responsibility reports. ... MORE
Reporting 2021
-
June 2, 2021Annual Shareholders' Meeting
-
August 5, 2021Quarterly Report Q2 2021
-
November 4, 2021Quarterly Report Q3 2021
Investor Relations
Jun 10, 2021
Evonik and Stanford University sign research collaboration: Evonik to market and develop new drug delivery platform for mRNA and gene therapy
Essen, Germany. Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). ... MORE
Investor Relations
Jun 02, 2021
Supervisory board extends contract with Christian Kullmann
Essen. Christian Kullmann, who has been chairman of Evonik's executive board since May 2017, will head this Essen-based specialty chemicals company for another five years. ... MORE
Investor Relations
May 06, 2021
Evonik more confident about full year after a strong first quarter
Evonik is more positive about its earnings for the year as a whole after posting a strong first quarter. ... MORE
Investor Relations
Apr 22, 2021
Start of production in record time: Evonik delivers first lipids from German facility to BioNTech
Essen, Germany. Evonik is helping to accelerate the production of the COVID-19 vaccine from Pfizer-BioNTech by suppling an essential component. ... MORE
Investor Relations
Apr 13, 2021
Evonik “Division Spotlight Series”: Nutrition & Care set to unleash its full potential in new and more focused setup
Evonik is hosting a “Division Spotlight Series” this year to give further insights into its three growth divisions. The series kicks off today with the spotlight on Nutrition & Care. ... MORE
Investor Relations
Mar 23, 2021
Evonik aims to generate additional sales of at least €350 million by 2030 with solutions for circular plastics
Essen, Germany. Evonik is pooling its activities for circular plastics in a global program. ... MORE
Further Information
Company
Financial data
Evonik is active in over 100 countries around the world. In fiscal 2018 more than 36,000 employees generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion. ... MORE
Company
Bonds & Rating
Evonik maintains a centralized approach to financing. Liabilities for credit and loans are fully guaranteed by Evonik Industries AG. ... MORE
Company
Key Figures Share
Here you find information about Evonik shares. ... MORE
Company
Contact & Service
You can find the contacts in the Investor Relations Department here. ... MORE
Company
Disclaimer
Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained. ... MORE
Company
Corporate Governance
As a globally active company, we have to comply with a wide range of statutory regulations and cultural standards. ... MORE
Investor Relations
Sustainable Investment (SRI)
We accept responsibility for our businesses, our employees, the environment and the society. ... MORE